Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up
The combination of MSC and MC therapy can reduce the incidence of chronic diabetes complications and improves metabolic control with mild side effects in T2DM patients.
Authors
- Zhixian Wu (ORCID: https://orcid.org/0000-0002-0708-6770)
- Shulin Huang (ORCID: https://orcid.org/0009-0006-2181-8073)
- Jianming Tan (ORCID: https://orcid.org/0000-0001-6968-4445)
- Jinquan Cai (ORCID: https://orcid.org/0000-0002-9502-769X)
- Shasha Li (ORCID: https://orcid.org/0000-0001-9177-8173)
- Jin Chen (ORCID: https://orcid.org/0000-0003-0794-3995)
- Weizhen Wu
- Lianghu Huang
Institutions
- Fujian Medical University (CN)
- Fuzhou General Hospital of Nanjing Military Command (CN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s13287-024-03907-w
- Citations
- 10
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 4.38
Funders
- Fujian Medical University